Publications by authors named "R F J Criado"
Drug-induced hypersensitivity syndrome, also known as DRESS syndrome, is a serious and potentially fatal reaction that occurs in response to prolonged use (generally between 14 and 60 days) of certain drugs, and which has no predilection for gender or age group. It is believed that DRESS syndrome has a genetic basis and results from the interaction between metabolites of certain pharmacological groups, reactivation of latent viruses (especially from the Herpesviridae family), and a cellular immune response. The classic manifestation of DRESS syndrome includes a generalized rash accompanied by fever, eosinophilia, lymphadenopathy, and systemic involvement such as hepatitis, nephritis, or pneumonitis.
View Article and Find Full Text PDFArticle Synopsis
- Long-term effectiveness and safety of omalizumab for Chronic Inducible Urticaria (CIndU) were evaluated in a large cohort across 14 specialized centers, revealing it to be highly effective for most patients.
- Out of 234 patients, 73% reported significant improvements while the median treatment duration exceeded 5 years, mainly due to disease control.
- Patient age was a predictor of treatment continuation, with older patients less likely to discontinue due to well-controlled disease, and CIndU subtype did not impact treatment response or duration.
Article Synopsis
- Atopic dermatitis is a chronic skin condition influenced by multiple factors including skin barrier issues, immune response, and genetic predisposition, affecting not just the skin but also other organs like the airways, eyes, and digestive system.
- The disease manifests differently based on various factors such as age, environment, and genetic background, leading to different phenotypes and health complications.
- Understanding the complex causes of atopic dermatitis helps in identifying effective treatments and managing triggering factors for better patient outcomes.
Importance: Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences.
View Article and Find Full Text PDFBackground: Patient-reported outcome measures (PROMs) are validated and standardized tools that complement physician evaluations and guide treatment decisions. They are crucial for monitoring atopic dermatitis (AD) and chronic urticaria (CU) in clinical practice, but there are unmet needs and knowledge gaps regarding their use in clinical practice.
Objecctive: We investigated the global real-world use of AD and CU PROMs in allergology and dermatology clinics as well as their associated local and regional networks.